· Published by Health Canada · Official notice
This is duplicated text of a letter from Guidant Canada Corporation
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
July 18, 2005
Subject: Important Safety Information on PULSAR® MAX, PULSAR, DISCOVERY®, MERIDIAN®, PULSAR MAX II, DISCOVERY II, VIRTUS PLUS® II, INTELIS II and CONTAK® TR devices
Dear Health Care Professional,
This letter is intended to inform you of important safety information regarding a subset of PULSAR MAX, PULSAR, DISCOVERY, MERIDIAN, PULSAR MAX II, DISCOVERY II, VIRTUS PLUS II, INTELIS II and CONTAK TR pacemakers manufactured between November 25, 1997 and October 26, 2000. Our records indicate that you have implanted or are monitoring patients with these devices. This letter advises physicians and their patients about the potential unanticipated device behaviors and is intended to limit adverse events.
Guidant's Cardiac Rhythm Management Quality System has recently determined that a hermetic sealing component utilized in these devices may experience a gradual degradation, resulting in a higher than normal moisture content within the pacemaker case late in the device's service life. This may lead to one or more of the following behaviors:
Important Note: While interrogation of the device may identify devices that have already experienced this failure mode, Guidant has not identified any test that will predict if a device will exhibit this failure mode in the future.
Important Note: While inappropriate accelerometer function has been observed in 60% of the failures reported to date, it cannot be relied upon as an early indicator of this failure mode.
Important Note: While disabling accelerometer function will mitigate inappropriate MSR pacing, moisture penetration can still cause the other behaviors described above, including loss of output.
Engineering analysis has determined that these clinical behaviors may be exhibited individually or in combination. As of July 11, 2005, Guidant has identified sixty-nine (69) devices that may have exhibited this failure mode. Fifty-two (52) such failures have been confirmed worldwide; four (4) devices are currently undergoing analysis, and thirteen (13) devices may have experienced this failure mode but were not returned to Guidant for confirmation.
Of the 78,000 devices originally distributed, approximately 28,000 devices remain implanted worldwide; 1,622 of these devices remain in service in Canada. No failures have been reported prior to forty-four (44) months of service, and the likelihood of occurrence increases with implant time. Guidant's modeling based on field experience and statistical life-table analysis predicts the rate of failure in the remaining active implanted devices to be between 0.17% and 0.51% over the remaining device lifetime. The actual occurrence rate and predicted rate may be greater than the stated numbers, because of underreporting and the limitations of projections.
The clinical behaviors associated with this failure mode can result in serious health complications. Guidant has confirmed twenty (20) reports of loss of pacing output associated with this failure mode, including five (5) patients experiencing syncope. Loss of pacing output has also been associated with reports of presyncope requiring hospitalization. Additionally, Guidant has received two reports of sustained MSR pacing in which heart failure may have developed in association with sustained high rate pacing. In one report, a patient whose device exhibited sustained MSR pacing was admitted to the hospital with multiple health issues and later expired. It is unknown if this device experienced the failure described above as the device was not returned and this failure mode could not be confirmed.
No other Guidant pacemakers including the Insignia™ family of pacemakers are affected by this action.
When determining the most appropriate patient management option, physicians should consider the unique needs of each individual patient, including pacemaker dependency, as well as the age and remaining service life of the pacemaker.
Guidant recommends the following:
| Accelerometer Status | Evaluation Critera |
|---|---|
| ON |
|
| OFF | Temporarily program the accelerometer ON and evaluate as describerd above. |
If any of these device behaviors are observed, contact your local Guidant representative or Guidant Technical Services for troubleshooting and recommendations.
A subset of the following model numbers are affected by this communication:
Devices Impacted
| Device Family | Model Numbers |
|---|---|
|
Table 1 footnotes
|
|
| PULSAR MAX | 1170, 1171, 1270 |
| PULSAR | 0470, 0870, 0970, 0972, 1172, 1272 |
| DISCOVERY | 1174, 1175, 1273, 1274, 1275 |
| MERIDIAN | 0476, 0976, 1176, 1276 |
| PULSAR MAX II | 1180, 1181, 1280 |
| DISCOVERY II | 0481, 0981, 1184, 1186, 1187, 1283, 1284, 1285, 1286 |
| CONTAK TR | 1241 |
| VIRTUS PLUS IITable 1 footnote * | 1380, 1480 |
| INTELIS IITable 1 footnote * | 1483, 1484, 1485, 1384, 1385, 1349, 1499 |
A list of affected devices specific to your clinic accompanies this communication if applicable.
Many of these devices are nearing or have exceeded their estimated longevity and have thus outlived their warranty. Even if a device is no longer covered by warranty, Guidant will provide a replacement device at no charge for pacemaker-dependent patients and other patients deemed by their physicians to be best served by replacement, provided the replacement occurs prior to the normal appearance of elective replacement indicators. This supplemental warranty program is available through December 31, 2005.
Guidant recognizes the impact of this communication on both you and your patients, and wants to reassure you that patient safety remains Guidant's primary concern. As always, if you have any questions regarding this communication, please contact:
The identification, characterization, and management of medical device-related adverse incidents are dependent on the active participation of health care professionals in adverse incident reporting programmes. Any occurrences of a specific adverse incident or other serious and/or unexpected adverse incidents in patients with PULSAR® MAX, PULSAR, DISCOVERY®, MERIDIAN®, PULSAR MAX II, DISCOVERY II, VIRTUS PLUS® II, INTELIS II and CONTAK® TR devices should be reported to Guidant Canada Corporation or Health Canada at the following addresses:
Guidant Canada Corporation
505 Apple Creek Boulevard, Unit #4
Markham, Ontario L3R 5B1
(800) 268-4487
(905) 947-5800
Any suspected adverse reaction can also be reported to:
Health Products and Food Branch Inspectorate
HEALTH CANADA
Address Locator: 3002C
Ottawa, Ontario K1A 0K9
Tel: The Inspectorate Hotline 1-800-267-9675
For other inquiries, please refer to contact information:
Marketed Health Products Directorate (MHPD)
Email: MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738
The Medical Devices Problem Report Form and Guidelines can be found on the Health Canada web site.
Sincerely,
original signed by
Scott Kadwell
Country Manager, Cardiac Rhythm Management
Guidant Canada Corporation